C

City Therapeutics

Develops RNAi therapeutics using trigger molecules

Vice President of Drug Safety and Pharmacovigilance

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • An MD or equivalent medical degree is required.
  • A minimum of 12 years of progressive experience in pharmacovigilance, drug safety, clinical development, or a closely related function within the biotechnology, pharmaceutical, or CRO industry is required.
  • Significant leadership experience, including responsibility for pharmacovigilance strategy, teams, governance, and outsourced operations, is required.
  • Demonstrated experience building or scaling a pharmacovigilance function within a clinical-stage biotechnology or pharmaceutical company is required.
  • Deep knowledge of global pharmacovigilance regulations and guidance, including pre- and post-marketing safety requirements in the United States and European Union, is required.
  • Demonstrated expertise in safety surveillance, signal management, aggregate reporting, risk management, and benefit-risk assessment is required.
  • Strong experience supporting clinical development programs and regulatory submissions, including integrated safety analyses and responses to health authority inquiries, is required.
  • Proven experience leading regulatory authority interactions and supporting successful pharmacovigilance inspections is required.
  • Experience overseeing CROs, pharmacovigilance service providers, safety databases, and other outsourced operations is required.
  • The role requires exceptional medical judgment, analytical thinking, scientific writing, and executive communication skills.
  • The candidate must be able to communicate complex safety information clearly and provide well-supported recommendations to senior leaders and cross-functional teams.
  • The candidate must be able to lead effectively in a fast-paced, growing organization while remaining willing to engage directly in critical deliverables.

Responsibilities

  • Develop and lead the company’s global pharmacovigilance and drug safety strategy in alignment with its clinical development plans and corporate objectives.
  • Serve as the company’s senior medical authority for safety matters, providing evidence-based benefit-risk assessments and recommendations to executive leadership.
  • Lead ongoing safety surveillance and signal detection, including signal validation, evaluation, prioritization, communication, and risk mitigation for development-stage assets.
  • Establish and lead Safety Review Committees and other safety-governance forums at the study, program, and portfolio levels.
  • Oversee the preparation, medical review, and approval of aggregate safety reports, including DSURs, PBRERs/PSURs, risk-management plans, and ad hoc safety assessments.
  • Provide expert safety input into clinical protocols, informed consent forms, Investigator’s Brochures, Clinical Study Reports, integrated summaries of safety, development plans, and regulatory submissions.
  • Lead the strategy and preparation of responses to regulatory authority inquiries involving safety matters, including the development of appropriate MedDRA search and analysis strategies.
  • Provide pharmacovigilance leadership for regulatory filings, health authority meetings, inspections, due diligence activities, and other critical company initiatives.
  • Represent Drug Safety and Pharmacovigilance in interactions with the FDA, EMA, MHRA, and other global regulatory authorities.
  • Build and maintain fit-for-purpose pharmacovigilance policies, procedures, templates, analytics, reporting infrastructure, quality controls, and inspection-readiness capabilities.
  • Oversee individual case safety report processing, expedited reporting, reconciliation activities, and safety database operations.
  • Partner with Clinical Development and Biometrics on safety data review, database adjudication, statistical analysis, and interpretation.
  • Select, oversee, and manage pharmacovigilance CROs and other external service providers, including performance, quality, contracts, budgets, invoices, and issue resolution.
  • Establish and monitor key performance indicators and quality metrics to ensure vendor adherence to regulatory requirements, contractual obligations, timelines, and quality standards.
  • Monitor changes in global pharmacovigilance regulations and industry standards, lead gap assessments, and implement necessary process improvements.
  • Build and develop the pharmacovigilance organization as the portfolio advances, including workforce planning, talent development, and succession planning.
  • Foster a culture of scientific rigor, collaboration, accountability, urgency, and commitment to patient safety.

Desired Qualifications

  • Board certification or relevant postgraduate clinical training is strongly preferred.
  • Experience in a biotechnology or start-up environment is strongly preferred.
  • Experience with RNA therapeutics or therapeutic areas relevant to the company’s pipeline is a plus.

About the Company

City Therapeutics

Develops RNAi therapeutics using trigger molecules

City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at City Therapeutics

See more jobs